US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

REIN THERAPEUTICS INC

1.88

+0.01000.53%

Post-market: 1.84-0.0400-2.13%16:48 EDT

Volume:184.06K

Turnover:364.72K

Market Cap:52.71M

PE:-0.96

High:2.10

Open:1.91

Low:1.84

Close:1.87

52wk High:2.40

52wk Low:1.02

Shares:28.04M

Float Shares:21.45M

Volume Ratio:1.62

T/O Rate:0.86%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9600

EPS(LYR):-1.9600

ROE:-139.87%

ROA:-31.75%

PB:-1.88

PE(LYR):-0.96

Loading ...

Overview Company News Filings

Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

Rein Therapeutics FY2025 operating loss narrows 22.2% to $(50.6) million; net loss narrows 20.7% to $(50) million

Rein Therapeutics Doses First Patient in Phase 2 IPF Trial of LTI-03

Rein Therapeutics enters $2.875 million promissory note financing deal

Rein Therapeutics Director Manuel C. Alves Aivado Resigns

Rein Therapeutics Unveils Pipeline Advancements in Pulmonary and Fibrosis Therapies

Rein Therapeutics Shares Fall 4%

THOMSON REUTERS

BUZZ-Rein Therapeutics rises as drug for lung‑scarring disease gets EU orphan status

Rein Therapeutics receives orphan drug designation from EMA for LTI-03

Rein Therapeutics Receives EMA Orphan Drug Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Receives Orphan Drug Designation From European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Rein Therapeutics Secures $2.5 Million Unsecured Note Financing from Funicular Funds

Rein Therapeutics: Elected to Terminate Standby Equity Purchase Agreement Dated July 29 Also Entered Into With Yorkville

THOMSON REUTERS

Rein Therapeutics Inc: No Penalties or Fees Incurred by Co in Connection With Its Election to Terminate Ppa and Sepa Agreements

THOMSON REUTERS

Rein Therapeutics Inc: Elected to Terminate Pre-Paid Advance Agreement Dated July 29 With Ya Ii Pn- SEC Filing

THOMSON REUTERS

Voss Capital Reports Acquisition of Rein Therapeutics Common Shares

Rein Therapeutics Announces New Scientific Publication Demonstrating Lti-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in Ipf

THOMSON REUTERS

Rein Therapeutics Reports LTI-03 Reduces Lung Scarring in IPF Study

Why Is Rein Therapeutics Stock Trading Higher On Monday?

Benzinga_recent_news

Rein Therapeutics Inc - Lti-03 Trial Initial Topline Data Expected in Q3 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RNTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","market":"US","secType":"STK","nameCN":"REIN THERAPEUTICS INC","latestPrice":1.88,"timestamp":1776888000000,"preClose":1.87,"halted":0,"volume":184057,"hourTrading":{"tag":"盘后","latestPrice":1.84,"preClose":1.88,"latestTime":"16:48 EDT","volume":596,"amount":1103.72,"timestamp":1776890934201,"change":-0.04,"changeRate":-0.021277,"amplitude":0.021277},"delay":0,"changeRate":0.005347593582887587,"floatShares":21451800,"shares":28039032,"eps":-1.959999,"marketStatus":"Closed","change":0.01,"latestTime":"04-22 16:00:00 EDT","open":1.91,"high":2.1,"low":1.84,"amount":364720.5594967,"amplitude":0.139037,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.959999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776931200000},"marketStatusCode":5,"adr":0,"listingDate":1498708800000,"exchange":"NASDAQ","adjPreClose":1.87,"preHourTrading":{"tag":"盘前","latestPrice":1.9,"preClose":1.87,"latestTime":"09:29 EDT","volume":1257,"amount":2409.619977,"timestamp":1776864577051,"change":0.03,"changeRate":0.016043,"amplitude":0.058824},"postHourTrading":{"tag":"盘后","latestPrice":1.84,"preClose":1.88,"latestTime":"16:48 EDT","volume":596,"amount":1103.72,"timestamp":1776890934201,"change":-0.04,"changeRate":-0.021277,"amplitude":0.021277},"volumeRatio":1.615003},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","floatShares":21451800,"roa":"-31.75%","roe":"-139.87%","lyrEps":-1.959999,"volumeRatio":1.615003,"shares":28039032,"dividePrice":0,"high":2.1,"amplitude":0.139037,"preClose":1.87,"low":1.84,"week52Low":1.02,"pbRate":"-1.88","week52High":2.4,"institutionHeld":0,"latestPrice":1.88,"eps":-1.959999,"divideRate":0,"volume":184057,"delay":0,"ttmEps":-1.959999,"open":1.91,"prevYearClose":1.16,"prevWeekClose":1.76,"prevMonthClose":1.3,"prevQuarterClose":1.3,"fiveDayClose":1.78,"twentyDayClose":1.22,"sixtyDayClose":1.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-26","symbol":"RNTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-11-14","symbol":"RNTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-08-14","symbol":"RNTX","fiscalQuarterEnding":"2025/06","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-05-15","symbol":"RNTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-04-07","symbol":"RNTX","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743998400000,"reportTimeType":"post","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1769054400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNTX","date":"2026-04-21","current":-1.056123,"percent":0.182965,"low":-2.000549,"twenty":-0.886076,"median":-0.580323,"eighty":-0.506198,"high":-0.401342,"avg":-0.752642,"sd":0.389931,"marketCap":51311428},"quantilePoints":[{"date":"2025-01-17","current":-1.459659,"twenty":-1.48337,"median":-1.467068,"eighty":-1.447804,"marketCap":42681903},{"date":"2025-01-24","current":-1.630077,"twenty":-1.576729,"median":-1.478183,"eighty":-1.446322,"marketCap":47665070},{"date":"2025-01-31","current":-1.467069,"twenty":-1.741219,"median":-1.496707,"eighty":-1.462623,"marketCap":42898563},{"date":"2025-02-07","current":-1.704171,"twenty":-1.704171,"median":-1.526344,"eighty":-1.459659,"marketCap":49831664},{"date":"2025-02-14","current":-1.741218,"twenty":-1.704171,"median":-1.578211,"eighty":-1.462623,"marketCap":50914961},{"date":"2025-02-21","current":-1.98573,"twenty":-1.794566,"median":-1.630077,"eighty":-1.468551,"marketCap":58064721},{"date":"2025-02-28","current":-1.533754,"twenty":-1.79753,"median":-1.630077,"eighty":-1.47596,"marketCap":44848497},{"date":"2025-03-07","current":-1.467069,"twenty":-1.753073,"median":-1.607848,"eighty":-1.468551,"marketCap":42898563},{"date":"2025-03-14","current":-1.496707,"twenty":-1.741218,"median":-1.552277,"eighty":-1.467069,"marketCap":43765200},{"date":"2025-03-21","current":-1.430022,"twenty":-1.733809,"median":-1.518935,"eighty":-1.461141,"marketCap":41815266},{"date":"2025-03-28","current":-1.311471,"twenty":-1.704171,"median":-1.507821,"eighty":-1.431504,"marketCap":38348715},{"date":"2025-04-04","current":-1.259605,"twenty":-1.704171,"median":-1.496707,"eighty":-1.416685,"marketCap":36832099},{"date":"2025-04-11","current":-0.545587,"twenty":-1.696762,"median":-1.481888,"eighty":-1.32629,"marketCap":34308123},{"date":"2025-04-17","current":-0.577063,"twenty":-1.667124,"median":-1.474478,"eighty":-1.296652,"marketCap":36287438},{"date":"2025-04-25","current":-0.640015,"twenty":-1.630077,"median":-1.467069,"eighty":-1.259605,"marketCap":40246068},{"date":"2025-05-02","current":-0.573565,"twenty":-1.630077,"median":-1.459659,"eighty":-0.64701,"marketCap":36067514},{"date":"2025-05-09","current":-0.601544,"twenty":-1.630077,"median":-1.437431,"eighty":-0.622528,"marketCap":37826905},{"date":"2025-05-16","current":-0.825375,"twenty":-1.622667,"median":-1.430022,"eighty":-0.622528,"marketCap":51902033},{"date":"2025-05-23","current":-0.696336,"twenty":-1.607848,"median":-1.415203,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-05-30","current":-0.696336,"twenty":-1.584138,"median":-1.407793,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-06-06","current":-0.705061,"twenty":-1.560428,"median":-1.311471,"eighty":-0.635119,"marketCap":43199785},{"date":"2025-06-13","current":-0.712292,"twenty":-1.550055,"median":-1.296652,"eighty":-0.639316,"marketCap":43642859},{"date":"2025-06-20","current":-0.592974,"twenty":-1.539682,"median":-1.259605,"eighty":-0.638616,"marketCap":36332127},{"date":"2025-06-27","current":-0.524276,"twenty":-1.524863,"median":-1.24849,"eighty":-0.622528,"marketCap":32122917},{"date":"2025-07-03","current":-0.54597,"twenty":-1.518935,"median":-0.809312,"eighty":-0.609134,"marketCap":33452141},{"date":"2025-07-11","current":-0.535123,"twenty":-1.515971,"median":-0.771713,"eighty":-0.598047,"marketCap":32787529},{"date":"2025-07-18","current":-0.506198,"twenty":-1.508562,"median":-0.726755,"eighty":-0.578462,"marketCap":31015230},{"date":"2025-07-25","current":-0.513429,"twenty":-1.504116,"median":-0.717873,"eighty":-0.562281,"marketCap":31458305},{"date":"2025-08-01","current":-0.421229,"twenty":-1.501152,"median":-0.708677,"eighty":-0.556817,"marketCap":25809102},{"date":"2025-08-08","current":-0.417509,"twenty":-1.496707,"median":-0.703515,"eighty":-0.543648,"marketCap":25581194},{"date":"2025-08-15","current":-0.434435,"twenty":-1.490779,"median":-0.698131,"eighty":-0.532953,"marketCap":26618269},{"date":"2025-08-22","current":-0.445213,"twenty":-1.481888,"median":-0.696336,"eighty":-0.524276,"marketCap":26334772},{"date":"2025-08-29","current":-0.445213,"twenty":-1.478924,"median":-0.689114,"eighty":-0.516321,"marketCap":26334772},{"date":"2025-09-05","current":-0.537801,"twenty":-1.474478,"median":-0.673872,"eighty":-0.514875,"marketCap":31811472},{"date":"2025-09-12","current":-0.425513,"twenty":-1.472996,"median":-0.650825,"eighty":-0.513429,"marketCap":25169516},{"date":"2025-09-19","current":-0.453092,"twenty":-1.467069,"median":-0.643512,"eighty":-0.506198,"marketCap":26800874},{"date":"2025-09-26","current":-0.470822,"twenty":-1.467069,"median":-0.629523,"eighty":-0.496939,"marketCap":27849604},{"date":"2025-10-03","current":-0.457032,"twenty":-1.465587,"median":-0.622528,"eighty":-0.470507,"marketCap":27033925},{"date":"2025-10-10","current":-0.539771,"twenty":-1.459659,"median":-0.615534,"eighty":-0.469167,"marketCap":31927997},{"date":"2025-10-17","current":-0.504312,"twenty":-1.455213,"median":-0.601544,"eighty":-0.470507,"marketCap":29830538},{"date":"2025-10-24","current":-0.496432,"twenty":-1.437431,"median":-0.598047,"eighty":-0.472004,"marketCap":29364436},{"date":"2025-10-31","current":-0.61069,"twenty":-1.435949,"median":-0.596299,"eighty":-0.477169,"marketCap":36122917},{"date":"2025-11-07","current":-0.61463,"twenty":-1.430022,"median":-0.598047,"eighty":-0.479267,"marketCap":36355968},{"date":"2025-11-14","current":-0.531891,"twenty":-1.430022,"median":-0.598047,"eighty":-0.480672,"marketCap":31461895},{"date":"2025-11-21","current":-0.616035,"twenty":-1.42854,"median":-0.59455,"eighty":-0.480672,"marketCap":36275207},{"date":"2025-11-28","current":-0.700851,"twenty":-1.422612,"median":-0.598047,"eighty":-0.480672,"marketCap":41269619},{"date":"2025-12-05","current":-0.620499,"twenty":-1.415203,"median":-0.603206,"eighty":-0.482843,"marketCap":36538070},{"date":"2025-12-12","current":-0.687459,"twenty":-1.415203,"median":-0.607107,"eighty":-0.492492,"marketCap":40481028},{"date":"2025-12-19","current":-0.575859,"twenty":-1.407793,"median":-0.606928,"eighty":-0.496432,"marketCap":33909432},{"date":"2025-12-26","current":-0.589251,"twenty":-1.390011,"median":-0.606928,"eighty":-0.496432,"marketCap":34698024},{"date":"2026-01-02","current":-0.517826,"twenty":-1.341109,"median":-0.603755,"eighty":-0.496432,"marketCap":30492203},{"date":"2026-01-09","current":-0.54461,"twenty":-1.311471,"median":-0.601544,"eighty":-0.497777,"marketCap":32069386},{"date":"2026-01-16","current":-0.517826,"twenty":-1.30258,"median":-0.596299,"eighty":-0.498849,"marketCap":30492203},{"date":"2026-01-23","current":-0.598179,"twenty":-1.296652,"median":-0.593762,"eighty":-0.499215,"marketCap":35223751},{"date":"2026-01-30","current":-0.638355,"twenty":-1.293688,"median":-0.598047,"eighty":-0.499741,"marketCap":37589526},{"date":"2026-02-06","current":-0.508898,"twenty":-1.277387,"median":-0.593762,"eighty":-0.500131,"marketCap":29966475},{"date":"2026-02-13","current":-0.52229,"twenty":-1.259605,"median":-0.589251,"eighty":-0.501948,"marketCap":30755066},{"date":"2026-02-20","current":-0.49997,"twenty":-1.259605,"median":-0.58056,"eighty":-0.49997,"marketCap":29440747},{"date":"2026-02-27","current":-0.535682,"twenty":-1.255159,"median":-0.578693,"eighty":-0.50005,"marketCap":31543658},{"date":"2026-03-06","current":-0.531218,"twenty":-1.154976,"median":-0.575859,"eighty":-0.50116,"marketCap":31280794},{"date":"2026-03-13","current":-0.571395,"twenty":-0.81895,"median":-0.571395,"eighty":-0.504312,"marketCap":33646568},{"date":"2026-03-20","current":-0.580323,"twenty":-0.79198,"median":-0.575859,"eighty":-0.504312,"marketCap":34172296},{"date":"2026-03-27","current":-0.566931,"twenty":-0.783866,"median":-0.57248,"eighty":-0.504336,"marketCap":33383705},{"date":"2026-04-02","current":-0.6803,"twenty":-0.771713,"median":-0.575859,"eighty":-0.504434,"marketCap":33927228},{"date":"2026-04-10","current":-0.860214,"twenty":-0.793249,"median":-0.580323,"eighty":-0.506198,"marketCap":42899718},{"date":"2026-04-17","current":-0.955793,"twenty":-0.871458,"median":-0.580323,"eighty":-0.506198,"marketCap":47666354},{"date":"2026-04-21","current":-1.028883,"twenty":-0.886076,"median":-0.580323,"eighty":-0.506198,"marketCap":51311428}],"updateTime":1776880647109},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624500191","title":"Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2624500191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624500191?lang=en_us&edition=fundamental","pubTime":"2026-04-02 23:00","pubTimestamp":1775142037,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating on Rein Therapeutics (RNTX) with a $10 price target after the company said it dosed the first patient in it...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-past-the-regulatory-uncertainty-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-past-the-regulatory-uncertainty-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","RNTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899156","title":"Rein Therapeutics FY2025 operating loss narrows 22.2% to $(50.6) million; net loss narrows 20.7% to $(50) million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899156","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899156?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:37","pubTimestamp":1774557475,"startTime":"0","endTime":"0","summary":"Rein published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.Net loss was USD 49.9 million, compared with a USD 62.9 million net loss a year earlier.Total operating expenses were USD 50.6 million, down 22.24%, including R&D expense of USD 11.0 million  and G&A expense of USD 10.9 million .Impairment loss on intangible assets was USD 28.7 million, down 22.43%, after the company paused development activities related to LTI-01 for an indefinite period.Cash and cash equivalents were USD 3.2 million, and management said this, together with USD 4.3 million of proceeds received under promissory notes issued in January and February 2026, is expected to fund operations into the second quarter of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL9Y2Y1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616340708","title":"Rein Therapeutics Doses First Patient in Phase 2 IPF Trial of LTI-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340708?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:02","pubTimestamp":1772542925,"startTime":"0","endTime":"0","summary":"Rein Therapeutics  announced it has dosed the first patient in its Phase 2 randomized, double-blind, placebo-controlled trial of LTI-03 for idiopathic pulmonary fibrosis following recent FDA clearance to resume the Phase 2 program. The study is expected to enroll about 120 patients across placebo, low-dose, and high-dose groups at sites in five countries and will monitor safety, tolerability, and lung function measures including forced vital capacity . Rein said enrollment is expected to continue through mid-2027, with interim data anticipated in the second half of 2026; the trial is currently active at five U.S. clinical sites and may expand to up to 50 sites.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. publi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL1SLSKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616733599","title":"Rein Therapeutics enters $2.875 million promissory note financing deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2616733599","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616733599?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:10","pubTimestamp":1772449807,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. entered into separate securities purchase agreements on Feb. 24 and 27, 2026 with three institutional investors for a private placement of unsecured promissory notes totaling $2.875 million in original principal amount, sold for $2.3 million reflecting a 20% original issue discount. The notes mature on the earlier of the company’s next qualifying securities financing raising at least $10 million in gross proceeds or June 30, 2026, and bear no interest other than the original issue discount.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3jz1g3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612235974","title":"Rein Therapeutics Director Manuel C. Alves Aivado Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2612235974","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612235974?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:38","pubTimestamp":1771537084,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. said board member Manuel C. Alves Aivado, M.D., Ph.D., resigned effective immediately. The company said his departure was not due to any disagreement over its operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL4DRDf7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605481737","title":"Rein Therapeutics Unveils Pipeline Advancements in Pulmonary and Fibrosis Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605481737","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605481737?lang=en_us&edition=fundamental","pubTime":"2026-01-22 01:12","pubTimestamp":1769015527,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc., a clinical-stage biotechnology company, has released a corporate presentation outlining its progress in developing therapies for orphan pulmonary and fibrosis indications. The company’s lead candidate, LTI-03, is being evaluated as a potential treatment for idiopathic pulmonary fibrosis , with Phase 2 clinical trials underway. According to the presentation, LTI-03 demonstrated a favorable safety profile in Phase 1 trials, with no identified safety issues at the highest tested dose. The therapy works through a dual mechanism aimed at promoting alveolar epithelial cell survival and inhibiting profibrotic signaling. Initial interim data from the Phase 2 trial is anticipated in the second half of 2026. Other pipeline programs include LTI-01 for loculated pleural effusions and additional candidates targeting multiple fibrotic and pulmonary conditions. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL9G9cy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604111993","title":"Rein Therapeutics Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604111993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604111993?lang=en_us&edition=fundamental","pubTime":"2026-01-20 22:34","pubTimestamp":1768919669,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL18Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604152021","title":"BUZZ-Rein Therapeutics rises as drug for lung‑scarring disease gets EU orphan status","url":"https://stock-news.laohu8.com/highlight/detail?id=2604152021","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604152021?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:30","pubTimestamp":1768915826,"startTime":"0","endTime":"0","summary":"BUZZ-Rein Therapeutics rises as drug for lungscarring disease gets EU orphan status** Shares of drug developer Rein Therapeutics RNTX.O rise 2.5% to $1.24 premarket ** Co says European regulators granted orphan drug status to its experimental therapy, LTI03, for idiopathic pulmonary fibrosis or IPF, a fatal lungscarring disease** IPF causes irreversible lung damage that makes breathing difficult** Co says early data from preclinical tests showed better survival and lung function** RNTX's LTI03 is a synthetic peptide aimed at protecting lung cells and blocking signals that drive scarring; drug also holds U.S. orphan status, co says** Co plans further trials in the U.S., UK, Germany, Poland and Australia ** As of last close, stock declined ~50% over the past year  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL4N3YL17R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604311596","title":"Rein Therapeutics receives orphan drug designation from EMA for LTI-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2604311596","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604311596?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:12","pubTimestamp":1768914746,"startTime":"0","endTime":"0","summary":"Rein Therapeutics (RNTX) announced that it has received orphan drug designation from the European Medicines Agency, EMA, for LTI-03, its lead drug ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-receives-orphan-drug-designation-from-ema-for-lti-03-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-receives-orphan-drug-designation-from-ema-for-lti-03-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","BK4081","RNTX","BK4539","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604113100","title":"Rein Therapeutics Receives EMA Orphan Drug Designation for LTI-03 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113100","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113100?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:01","pubTimestamp":1768914118,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has received orphan drug designation from the European Medicines Agency  for its lead drug candidate, LTI-03, targeting idiopathic pulmonary fibrosis . The designation, entered under EU/3/25/3188, follows a positive opinion from the EMA's Committee for Orphan Medicinal Products and adoption by the European Commission. This regulatory milestone provides Rein Therapeutics with regulatory incentives such as reduced development fees, potential market exclusivity upon approval, and enhanced development efficiency. No other beneficiary organizations were mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief vi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL8Vmn0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","NDAQ","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","BK4139","LU2210149790.SGD","LU2210150020.SGD","BK4588","RNTX","BK4585","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604113995","title":"Rein Therapeutics Receives Orphan Drug Designation From European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113995?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA2G504P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604914625","title":"Rein Therapeutics Secures $2.5 Million Unsecured Note Financing from Funicular Funds","url":"https://stock-news.laohu8.com/highlight/detail?id=2604914625","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604914625?lang=en_us&edition=fundamental","pubTime":"2026-01-17 06:26","pubTimestamp":1768602375,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has entered into a new financing agreement with Funicular Funds, LP, managed by Cable Car Capital, LP. Under the terms of the securities purchase agreement signed on January 15, 2026, Rein Therapeutics issued and sold an unsecured promissory note with a principal amount of $2,500,000 to Funicular in a private placement. Funicular paid $2,000,000 for the note, reflecting a 20% original issue discount. The note matures on the earlier of the closing of Rein Therapeutics' next capital raise of at least $10 million or June 30, 2026. No interest is payable on the note beyond the original issue discount. The transaction was exempt from SEC registration requirements under Section 4 and Rule 506 of Regulation D.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL8M4BpN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590854400","title":"Rein Therapeutics: Elected to Terminate Standby Equity Purchase Agreement Dated July 29 Also Entered Into With Yorkville","url":"https://stock-news.laohu8.com/highlight/detail?id=2590854400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590854400?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:26","pubTimestamp":1765491982,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH16O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590544003","title":"Rein Therapeutics Inc: No Penalties or Fees Incurred by Co in Connection With Its Election to Terminate Ppa and Sepa Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2590544003","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590544003?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:26","pubTimestamp":1765491982,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH16O:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590440065","title":"Rein Therapeutics Inc: Elected to Terminate Pre-Paid Advance Agreement Dated July 29 With Ya Ii Pn- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590440065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590440065?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:26","pubTimestamp":1765491982,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH16O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584556961","title":"Voss Capital Reports Acquisition of Rein Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584556961","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584556961?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:31","pubTimestamp":1763505089,"startTime":"0","endTime":"0","summary":"Voss Capital, LP, along with Voss Value Master Fund, LP, Voss Value-Oriented Special Situations Fund, LP, Voss Advisors GP, LLC, and Travis W. Cocke, reported the acquisition of common shares of Rein Therapeutics Inc. as beneficial owners. Other reporting beneficial owners were also included in the filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLbz5wYZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Voss Capital Reports Acquisition of Rein Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581060663","title":"Rein Therapeutics Announces New Scientific Publication Demonstrating Lti-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in Ipf","url":"https://stock-news.laohu8.com/highlight/detail?id=2581060663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581060663?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:31","pubTimestamp":1762432279,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI0RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581523060","title":"Rein Therapeutics Reports LTI-03 Reduces Lung Scarring in IPF Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2581523060","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581523060?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432215,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has announced new scientific findings regarding its lead drug candidate, LTI-03, for idiopathic pulmonary fibrosis . A recently posted preprint on medRxiv describes results from a randomized, dose-escalation clinical study evaluating inhaled LTI-03 in IPF patients. The study assessed safety, pharmacokinetics, and biological activity. According to the report, LTI-03 was generally well tolerated and was associated with reductions in multiple fibrosis-associated biomarkers, as well as preservation of alveolar epithelial type II progenitor cells, which are important for lung repair. These findings build on previous results and provide support for the ongoing global Phase 2 RENEW trial of LTI-03. The results have already been made available in the preprint publication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL8yvX1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","RNTX","LU0314104364.USD","IE00BGHQF748.EUR","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","BK4585","BK4588","LU2095319765.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580524942","title":"Why Is Rein Therapeutics Stock Trading Higher On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2580524942","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580524942?lang=en_us&edition=fundamental","pubTime":"2025-11-04 02:17","pubTimestamp":1762193820,"startTime":"0","endTime":"0","summary":"Rein Therapeutics shares rise after the FDA lifts clinical hold on its Phase 2 RENEW trial for idiopathic pulmonary fibrosis treatment LTI-03.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/03/medical-research-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/03/medical-research-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/11/48600068/why-is-rein-therapeutics-stock-trading-higher-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/11/48600068/why-is-rein-therapeutics-stock-trading-higher-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["RNTX","LENZ","BK4139","BK4539","FVC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580290271","title":"Rein Therapeutics Inc - Lti-03 Trial Initial Topline Data Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2580290271","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580290271?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:30","pubTimestamp":1762173001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA3NV0DJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}